Lei Wang

Dr. Lei Wang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
XZXiang Zhang
Xiang Zhang
LJLin-Tao Jia
Lin-Tao Jia
SHSi-Jun Hu
Si-Jun Hu
JZJing Zhao
Jing Zhao
AYAngang Yang
Angang Yang
The MYC oncogene is overexpressed in hepatocellular carcinoma (HCC) and has been associated with widespread microRNA (miRNA) repression; however, the underlying mechanisms are largely unknown. Here, we report that the c-Myc oncogenic transcription factor physically interacts with enhancer of zeste homolog 2 (EZH2), a core enzymatic unit of polycomb repressive complex 2 (PRC2). Furthermore, miR-101, an important tumor-suppressive miRNA in human hepatocarcinomas, is epigenetically repressed by PRC2 complex in a c-Myc-mediated manner. miR-101, in turn, inhibits the expression of two subunits of PRC2 ( EZH2 and EED ), thus creating a double-negative feedback loop that regulates the process of hepatocarcinogenesis. Restoration of miR-101 expression suppresses multiple malignant phenotypes of HCC cells by coordinate repression of a cohort of oncogenes, including STMN1 , JUNB , and CXCR7 , and further increases expression of endogenous miR-101 by inhibition of PRC2 activation. In addition, co-overexpression of c-Myc and EZH2 in HCC samples was closely associated with lower expression of miR-101 ( P < 0.0001) and poorer prognosis of HCC patients ( P < 0.01). Conclusions : c-Myc collaborates with EZH2-containing PRC2 complex in silencing tumor-suppressive miRNAs during hepatocarcinogenesis and provides promising therapeutic candidates for human HCC. (Hepatology 2014;59:1850–1863)

1 January 2020 in Theranostics
Verified
Journal Article
Open access
QZQian-Feng Zhang
Qian-Feng Zhang
JLJia Li
Jia Li
KJKuo Jiang
Kuo Jiang
RWRui Wang
Rui Wang
JGJun-Li Ge
Jun-Li Ge
BCBi-Liang Chen
Bi-Liang Chen
Great progress has been made in the field of tumor immunotherapy in the past decade. However, the therapeutic effects of immune checkpoint blockade (ICB) against ovarian cancer are still limited. Recently, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6i) has been reported to enhance antitumor immunity in preclinical models. The combined use of CDK4/6i and ICB may be beneficial, but the effects of CDK4/6is on the tumor immune microenvironment and whether they can synergize with ICB in treating ovarian cancer remain unknown.

22 May 2013 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
ZGZhang-Yan Guo
Zhang-Yan Guo
RZRui Zhang
Rui Zhang
BXBo Xin
Bo Xin
RCRui Chen
Rui Chen
AYAn-Gang Yang
An-Gang Yang
The POU transcription factor OCT4 is a pleiotropic regulator of gene expression in embryonic stem cells. Recent studies demonstrated that OCT4 is aberrantly expressed in multiple types of human cancer; however, the underlying molecular mechanism remains largely unknown. In this study, we report that OCT4-pg4, a pseudogene of OCT4, is abnormally activated in hepatocellular carcinoma (HCC). The expression level of OCT4-pg4 is positively correlated with that of OCT4, and both gene transcripts can be directly targeted by a tumor-suppressive micro RNA miR-145. We find that the non-coding RNA OCT4-pg4 is biologically active, as it can upregulate OCT4 protein level in HCC. Mechanistic analysis revealed that OCT4-pg4 functions as a natural micro RNA sponge to protect OCT4 transcript from being inhibited by miR-145. In addition, our study also showed that OCT4-pg4 can promote growth and tumorigenicity of HCC cells, thus exerting an oncogenic role in hepatocarcinogenesis. Furthermore, survival analysis suggests that high OCT4-pg4 level is significantly correlated with poor prognosis of HCC patients. Taken together, our finding adds a new layer of post-transcriptional regulation of OCT4 and sheds new light on the treatment of human HCC.

1 January 2018 in Theranostics
Verified
Journal Article
Open access
GLGuo-Yin Li
Guo-Yin Li
WWWei Wang
Wei Wang
JSJian-Yong Sun
Jian-Yong Sun
BXBo Xin
Bo Xin
XZXiang Zhang
Xiang Zhang
LWLei Wang
Lei Wang
Transforming growth factor-β (TGF-β) has received much attention as a major inducer of epithelial-mesenchymal transition (EMT) during cancer progression, mainly by activating a set of pleiotropic transcription factors including SNAI2/Slug. However, the involvement of long non-coding RNAs (lncRNAs) in TGF-β-induced Slug activation and EMT remains largely unknown.

21 May 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
GLGuoyin Li
Guoyin Li
QXQiaosheng Xie
Qiaosheng Xie
ZYZhiwei Yang
Zhiwei Yang
LWLei Wang
Lei Wang
XZXiang Zhang
Xiang Zhang
LJLintao Jia
Lintao Jia

28 January 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GLGuoyin Li
Guoyin Li
ZSZewen Song
Zewen Song
WCWu Changjing
Wu Changjing
XLXiaoYan Li
XiaoYan Li
LZLiping Zhao
Liping Zhao
LWLei Wang
Lei Wang
Cumulative evidence indicates that the abnormal regulation of the NEDD4 family of E3-ubiquitin ligases participates in the tumorigenesis and development of cancer. However, their role in lung adenocarcinoma (LUAD) remains unclear. This study comprehensively analyzed the NEDD4 family in LUAD data sets from public databases and found only NEDD4L was associated with the overall survival of LUAD patients. Gene set enrichment analysis (GSEA) indicated that NEDD4L might be involved in the regulation of mTORC1 pathway. Both cytological and clinical assays showed that NEDD4L inhibited the activity of the mTOR signaling pathway. In vivo and in vitro experiments showed that NEDD4L could significantly inhibit the proliferation of LUAD cells. In addition, this study also found that the expression of NEDD4L was regulated by EGFR signaling. These findings firstly revealed that NEDD4L mediates an interplay between EGFR and mTOR pathways in LUAD, and suggest that NEDD4L held great potential as a novel biomarker and therapeutic target for LUAD.